Search

Your search keyword '"Kritikos V"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Kritikos V" Remove constraint Author: "Kritikos V"
112 results on '"Kritikos V"'

Search Results

1. The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients

2. Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation

3. Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases

4. Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection

5. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project)

6. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

9. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.

11. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

12. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

13. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

14. The evolving algorithm of biological selection in severe asthma

15. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

16. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

17. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

19. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

20. Treatable traits can be identified in a severe asthma registry and predict future exacerbations

21. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

22. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)

23. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)

24. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices

25. Working while unwell: Workplace impairment in people with severe asthma

26. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA)

27. Working while unwell: Workplace impairment in people with severe asthma

28. Medication-related costs of rhinitis in australia: A nostradata cross-sectional study of pharmacy purchases

29. Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study.

30. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly ( MACVIA ‐ ARIA ) ‐ EIP on AHA Twinning Reference Site ( GARD research demonstration project)

31. Severe asthma is associated with work productivity loss, activity impairment and reduced quality of life.

32. Characterisation of severe asthma phenotypes via a severe asthma registry: The severe asthma web-based database.

33. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

34. Real‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria

35. Clinical Effectiveness Of Omalizumab In Severe Allergic Asthma Above The Recommended Dosing Range: The Australian Xolair Registry

36. EFFECTIVENESS AND RESPONSE PREDICTORS OF OMALIZUMAB IN A SEVERE ALLERGIC ASTHMA POPULATION WITH A HIGH PREVALENCE OF COMORBIDITIES: THE AUSTRALIAN XOLAIR REGISTRY

37. Factors influencing pharmacy students’ attitudes towards pharmacy practice research and strategies for promoting research interest in pharmacy practice

38. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

39. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

40. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases: Review

41. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma.

42. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.

43. The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy.

44. Uncovering the Burden of Rhinitis in Patients Purchasing Nonprescription Short-Acting β-Agonist (SABA) in the Community.

45. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.

46. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air ® approach.

47. Management of allergic rhinitis symptoms in the pharmacy Pocket guide 2022.

48. Exploring General Practitioners' Preferences and Experience with Respiratory Inhaler Devices.

49. Perceptions, attitudes, and behaviors of short-acting beta 2 agonist users: an Australian cross-sectional community pharmacy-based study.

50. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.

Catalog

Books, media, physical & digital resources